Give news about iova

Here is the relevant news and analysis:1. Iovance Biotherapeutics Inc (IOVA) Pre-Market Momentum: Iovance Biotherapeutics Inc (IOVA) experienced a 7.09% pre-market increase. It has an overall score of 77, indicating better value than 77% of stocks. The short-term technical score is 60, reflecting recent neutral trading patterns.2. Positive Sentiment for IOVA: Iovance Biotherapeutics Inc (IOVA) received a bullish score from the InvestorsObserver Stock Sentiment Indicator. This reflects positive investor sentiment in the short term, independent of the company's fundamental strength.3. Strong Performance in Premarket Trading: IOVA saw a significant 22.19% increase in pre-market trading, with an overall score of 83, indicating better value than 83% of stocks. The short-term technical score is 60, suggesting a neutral trading pattern in the past month.4. FDA Approval for Melanoma Drug Amtagvi: Iovance Biotherapeutics Inc (IOVA) received FDA approval for its T cell immunotherapy, Amtagvi, for advanced melanoma treatment, marking a 32.7% post-hours trading increase. This is the first one-time T cell therapy approved for solid tumor cancer by the FDA.Analysis: Iovance Biotherapeutics Inc (IOVA) shows strong pre-market performance and positive investor sentiment, with recent FDA approval of Amtagvi for advanced melanoma treatment. This could signal potential growth for IOVA in the biotech sector. However, investors should consider the stock's recent neutral trading patterns and the risks associated with the biotech industry. In-depth research on IOVA's long-term prospects and market competition is essential before making investment decisions.